In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Nathan P WiederholdFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122 Charlotte BissonUniversity of California, Berkeley, California, USA.
David A StevensDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Chiung-Yu HungDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-1091-3420 Jose Lopez-RibotDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-1992-3270 Thomas F PattersonDepartment of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-9513-7127 George R Thompson IiiDepartment of Internal Medicine, Division of Infectious Diseases and the Department of Medical Microbiology and Immunology, University of California-Davis Medical Center, Sacramento, California, USA.
Funding
Screening Repurposing Libraries for the Identification of Drugs with Novel anti-Coccidioidal ActivityU19AI166761 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI CHIUNG-YU HUNG, Jose L. Lopez-Ribot · 2022 to 2026
$8.1MNIAID/NIH U19AI166761
6 · The paper itselfAbstract
Treatment of symptomatic patients with coccidioidomycosis often involves the use of triazole antifungals. There is concern for reduced susceptibility of
Indexed as
Antifungal AgentsAzolesCoccidioidesCoccidioidomycosisDrug Resistance, FungalFluconazoleHumansItraconazoleMicrobial Sensitivity TestsTriazolesUnited StatesVoriconazoleAntifungal AgentsAzolesFluconazoleItraconazoleposaconazoleTriazolesVoriconazoleantifungal susceptibility testingCoccidioidescoccidioidomycosisendemic mycosesfluconazoleisavuconazoleitraconazoleposaconazolevoriconazole
Identifiers
PMID42690180
PMCPMC13688981
What OpenQuestion holds
Textmetadata
Read underepoch 390